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Abstract 
A novel optical biochip for immunosuppressants detection in transplanted patients is described. The optical working of the chip, 
based on total internal reflection fluorescence and consisting of two bonded polymeric parts, a Zeonex 330 slide and a Topas foil 
was demonstrated. In parallel, a heterogeneous competitive immunoassay for tacrolimus was implemented using a thirteen-
microchannel optical chip interrogated by an in-house optical platform based on fluorescence anisotropy and the bioassay 
conditions were optimized: a limit of detection of 0.11 ng/mL, a limit of quantification of 0.57 ng/mL and a coefficient of 
variation of 25% were achieved.  
© 2014 The Authors. Published by Elsevier Ltd. 
Peer-review under responsibility of the scientific committee of Eurosensors 2014.  
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1. Introduction 
The measurement of immunosuppressants is essential in transplanted patient in order to avoid the rejection of the 
transplanted organ [1]. The correct administration window is very narrow and changes from patient to patient: if a 
low dosage is ineffective, a high dosage can cause an excessive inhibition of the immune response, leading to an 
increased risk for the patient life. Generally a single drug is not sufficient and a combination of immunosuppressive 
drugs is necessary, each of them with a different target [2]. Typical examples are given by the inhibitors of 
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calcineurin, a protein associated to the activation of the T cells of the immune system, such as Cyclosporin A and 
Tacrolimus (FK 506), by the inhibitors of the mammalian mTOR proteins, rapamycin (sirolimus) and everolimus 
and by mycophenolic acid, which inhibits an enzyme needed for the growth of T- and B-cells.  
General practice is the periodical administration of the drugs (e.g. twice daily or, in case the drugs are applied as 
an infusion, over several hours) with the measurement of the drug concentration in whole blood or plasma before its 
next administration with the purpose to avoid overdosing. This provides the information on the trough level, which is 
the lowest concentration reached by a drug before the next dose is administered. Recent studies showed that higher 
clinical indication is given by the area under the concentration time curve (AUC) of immunosuppressant 
concentrations, since this value is better correlated with efficiency and side effects of immunosuppressive therapy 
than the trough level. It is apparent that a continuous monitoring of these analytes would provide the best 
information to physicians in order to define their appropriate dosage, providing the correct information not only on 
the actual drug levels right value but also on the pharmacokinetics [3]. On the other hand, a continuous measurement 
of these bioanalytes is impossible, being the measurement based on laboratory immunoassay or high-performance 
liquid chromatography (HPLC) with ultraviolet (UV) or mass spectrometry (MS), with the last one considered at the 
moment the reference method. Also the possibility of the measurements of these bioanalytes close to the bed 
patients, without the delivery of the biological samples to a central lab, would imply an evident step forward in this 
area since it would provide the result of the measurement in a shorter time. From this point of view, immunoassay is 
a very promising technique, being many immunoassay-based POCT devices already available on the market.  
With the final purpose of the development of a POCT device for the detection of immunosuppressive drugs, a 
novel optical biochip was developed, based on total internal reflection fluorescence (TIRF) and at the same time 
optimized conditions for tacrolimus detection were achieved by the implementation of a heterogeneous competitive 
immunoassay using a thirteen-microchannel optical chip interrogated by an optical platform based on fluorescence 
anisotropy. 
2. Materials and methods 
All the used chemicals were of analytical-reagent grade and were purchased from Sigma, if not otherwise 
specified. Prionex® Calbiochem was from Merck Millipore (Darmstadt, Germany). Derivative of tacrolimus 
(tacrolimus-COOH) was provided by the group of Prof. G. Orellana (Universidad Complutense de Madrid, Spain) 
[4]. Tacrolimus and anti-tacrolimus monoclonal antibody from mouse (IgM, clone FK1) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Donkey anti-mouse IgM labelled with Alexa Fluor® 647 (Jackson 
Immunoresearch, West Grove, PA) was used as secondary antibody. Streptavidin labelled with ATTO647N was 
purchased from Jena Bioscience (Jena, Germany). 
A preliminary evaluation for the optimization of different parameters for the tacrolimus assay was carried out on 
optical biochips in PMMA interrogated with an in-house stand-alone optical platform developed within the 
European project Careman [5]. The chip, produced by injection molding, is constituted by 13 microchannels through 
which the sample flows. The sensing layer, where the immunochemical reaction takes place, is located on the upper 
part of each microchannel which is COOH-functionalized. The tacrolimus derivative was immobilized onto the 
channels via a carbodiimide crosslinking method: the carboxylic groups on the channels and on the tacrolimus 
derivative were activated by means of 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) (200 mM) and N-
Hydroxysuccinimide (NHS) (50 mM) and the immobilization of the activated tacrolimus derivative was conducted 
via crosslinking with diethylenetriamine 1 M pH 8.5 in H2O for 1 h. After blocking the surface with Prionex (5 
mg/mL), the competitive assay was performed with the following protocol: 
- incubation of tacrolimus with anti-tacrolimus Ab (IgM, FK1) (0.001 mg/mL) for 30 minutes; 
- pumping of the incubated solution within the chip at a flow-rate of 50 PL/min for 30 minutes; 
- pumping of anti-IgM Ab labelled with Alexa Fluor 647 (0.001 mg/mL) at a flow-rate of 50 PL/min for 30 
minutes. 
Between each step, a washing with PBS and PBS with the addition of Tween 20 (0.05 %) for 1 minute at a flow 
rate of 200 PL/min was carried out. Regeneration of the channels was conducted with guanidinium hydrochloride 6 
M pH 1.5 for 30 sec. 
Topas foil (thickness: 140 μm) and Zeonex 330 slide (thickness: 1 mm) were gently provided by microfluidic 
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ChipShop, Jena, Germany; the prism for optical coupling was an equilateral prism with the dimension of 10 mm 
(Thorlabs, PS850 - F2 Equilateral Dispersive Prism). Fluorescence detection was performed with an Andor 
Shamrock 303 Spectrometer; the laser source was an HeNe with emission at 632.8 nm and 10 mW of emitted optical 
power; the emitted light was filtered by means of a long-pass interference filter (Thorlabs FEL650). The ray tracing 
analysis was performed by means of an ad hoc Matlab program. 
3. Results and discussion 
A calibration curve was achieved for tacrolimus, performed onto 5 different PMMA multichannel biochips with 
the protocol described in Section 2: a limit of detection (LOD) of 0.11 ng/mL, a limit of quantification (LOQ) of 
0.57 ng/mL and a coefficient of variation (CV%) of 25% were achieved. The assay was repeated with tacrolimus 10 
ng/mL after regeneration and comparable results with respect to the first assay were achieved (Figure 1) 
Unspecific adsorption was also evaluated by exposing the sensing surface, coated with the tacrolimus derivative 
and passivated with Prionex, to the labelled anti-IgM Ab (0.001 mg/ml) without the anti-tacrolimus antibody. The 
resulting fluorescence (2.3 x 106 a.u.), compared with the signal achieved with the anti-tacrolimus antibody (2.4 x 
107 a.u.), evidences low level of unspecific adsorption. A very low signal (8.1 x 104 a.u.) was also observed after 
exposing the COOH functionalized PMMA surface, solely blocked with the passivating solution, to the labelled 
anti-IgM Ab (0.001 mg/ml). 
Figure 2A shows the design of the novel optical chip based on TIRF: it consists of two parts: a top polymer part 
properly shaped with a trapezoidal transversal cross section with refractive index n2 and a bottom thin polymer foil 
with refractive index n1. The refractive indices are chosen so that n1>n2. The microfluidic channel is constituted by a 
rectangular groove on the bottom side of the trapezium shaped polymer, with the chemical sensing layer located on 
the lower side of the microchannel. Due to its higher refractive index, the bottom foil is able to guide the excitation 
light- coming from an external light source - by total internal reflection. In such a way, the guided light excites, by 
evanescent field, the fluorescent sensing-layer immobilized onto the fluidic microchannel. Thanks to the proper 
shape of the top part and since the emission of fluorescence is not isotropic, due to the closeness of the fluorophore 
to the interface [6], the emitted fluorescence is mainly coupled inside the denser plastic foil and is reflected back at 
the air/plastic interface by total reflection, since the incidence angle is greater than the total reflection angle at this 
interface. When the reflected light impinges the interface between the plastic foil and the trapezium shaped polymer, 
since n1 is greater than n2, the light is refracted and enters the less dense polymer. With the proper choice of the 
inclination of the lateral side of the trapezoidal shaped polymer, the light is driven toward the photodetecting 
apparatus placed on the top of the chip. The multianalyte capability is assured by the presence of multiple channels 
in parallel. 
A two channel prototype was manufactured using a top Zeonex 330 slide (thickness: 1 mm, refractive index: 
1.509) and a bottom Topas foil (thickness: 140 μm, refractive index: 1.53), bonded together by means of 
temperature-based solvent technique. The height, the width and the length of the microchannel are 100 μm, 600 μm, 
and 10 mm, respectively. The dimensions of the trapezoidal section of the Zeonex 330 are the following: the two 
 
Fig. 1. Comparison among the results of the assay on tacrolimus 10 ng/mL repeated on the same channels after regeneration with guanidinium 
hydrochloride.  
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basis are 1.47 mm and 3.2 mm and the height is 1.5 mm. The α angle of 60° assures the total reflection of the 
emitted fluorescent along the lateral sides of the trapezoidal Zeonex. The optical working of the chip was verified by 
implementing a fluorescent layer constituted by Streptavidin labelled with ATTO647N within the microchannel; 
prism coupling is used to couple the light from the laser to the Topas film [5]. The fluorescence emitted light was 
collected from the top of the chip by means of a 200 μm multimode optical fiber, was filtered by means of the long-
pass interference filter and detected by the Andor spectrometer. 
Figure 2B shows the fluorescence distribution detected on the top of the trapezoidal shaped Zeonex, achieved by 
means of a transversal scanning with the optical fibre connected to the spectrometer.  
4. Conclusions 
The design of a novel biochip for immunosuppressants detection in transplanted patients was presented and 
preliminary tests on the bioassay implementation for tacrolimus detection were successfully performed. The 
tacrolimus bioassay was characterized by a LOD of 0.11 ng/mL, a LOQ of 0.57 ng/mL and a CV% of 25%. 
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Fig.2. (A) transversal cross section of the channel of the designed optical chip, with the ray tracing simulation of the fluorescence emitted by 
sensing layer; (B) fluorescence transversal distribution collected at the top of the Zeonex. 
